Dr. Stephen Levine Reflects on 40 Years in Gender Medicine. - Original Rebels Series (#21
10 July 2025
With Dr. Stephen B. Levine
North America
Dr Stephen Levine co-founded a US gender clinic in 1974, chaired a WPATH Standards of Care committee, and left the organisation in 2002 as science yielded to advocacy. His account of a profession that became intolerant of doubt maps closely onto the Cass Review's finding that gender medicine in the English-speaking world lacked the evidence base its practitioners claimed. Both arrive at the same point: the field has not known what it claimed to know.
Dr Stephen Levine has spent more than five decades treating patients with gender dysphoria, beginning at one of the first gender identity clinics established in the United States, in 1974. He went on to chair the committee that produced the fifth edition of what would become the World Professional Association for Transgender Health Standards of Care — the guidelines that have shaped clinical practice globally, including in the UK, for decades. He left WPATH in 2002 when he judged that the organisation had moved from scientific inquiry to ideological advocacy. That decision, and the professional isolation that followed, forms the backdrop to this conversation. Levine describes a field that once approached gender dysphoria with genuine curiosity — attempting to understand its causes, its natural history, and its relationship to other psychological conditions — and charts how that curiosity was gradually displaced by a settled narrative. Where clinicians once debated, they came to proclaim. Peer review at professional conferences gave way, by his account, to booing those who asked the wrong questions. The mechanism by which medicine hardened into ideology is not abstract: Levine was present for it, and names it plainly. One of the specific claims he addresses is the widely cited statistic that regret rates following gender-related medical treatment run at around two per cent. He challenges this figure as a product of inadequate follow-up rather than robust evidence. This bears directly on the conclusions of the Cass Review, published in England in 2024, which found that the evidence base for paediatric gender medicine was of remarkably poor quality and that outcomes data had not been systematically gathered. Both Levine and Hilary Cass arrive, from different directions, at the same fundamental point: the field has not known what it claimed to know. The conversation also addresses the psychological complexity that Levine believes has been lost from clinical assessment. He discusses how presentations of gender dysphoria often intersect with other conditions and with difficulties in forming intimate relationships, and argues that reducing every case to an innate gender identity forecloses the clinical questions that might actually help patients. This is consistent with the Cass Review's call for comprehensive psychological assessment rather than affirmation-only pathways, and with NHS England's subsequent decision to restrict puberty blocker prescribing to research settings. What makes Levine's account particularly significant for UK observers is that he is not an outsider critic: he was a founding figure within the very institutions whose transformation he describes. When he asks how many people must be harmed before a treatment is reconsidered, the question carries the weight of someone who helped build the system he now scrutinises. That question has already generated policy responses in England — the closure of the Tavistock's Gender Identity Development Service, the Cass Review's interim and final reports, and NHS England's revised clinical guidance — but Levine's testimony suggests the professional culture that resisted scrutiny has not yet fully reckoned with what it got wrong.
